« Back
Home /
Avibactam (free acid)

Avibactam (free acid)

Item no.	HY-14879-10mM
Manufacturer	MedChem Express
CASRN	1192500-31-4
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.22
Citations	[1]Ehmann DE, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8.\|[2]Livermore DM, et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother. 2012 Jun;67(6):1354-8.\|[3]Berkhout J, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304.\|[4]Zhang W, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018 Nov 21;7:142. Antibiotics (Basel). 2023 Jul 20, 12(7), 1212.\|Antibiotics (Basel). 2024 May 1, 13(5), 416.\|Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02260-16.\|Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01809-18.\|Antimicrob Agents Chemother. 2019 Aug 23;63(9):e01374-19.\|Antimicrob Agents Chemother. 2019 Sep 16;63(12):e01515-19.\|Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02025-19.\|Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00409-20.\|Antimicrob Agents Chemother. 2023 May 18;e0160322.\|Antimicrob Agents Chemother. 2023 May 31;e0033923.\|Antimicrob Agents Chemother. 2023 Sep 6;e0052823.\|Antimicrob Agents Chemother. 2023 Sep 8;e0030123.\|Antimicrob Agents Chemother. 2024 Oct 4:e0077524.\|Biomed Res Int. 2018 Jul 2;2018:3579832. \|BMC Microbiol. 2020 Jun 29;20(1):187.\|BMC Microbiol. 2019 Nov 1;19(1):240.\|Eur J Clin Microbiol Infect Dis. 2024 Dec 20.\|Eur J Clin Microbiol Infect Dis. 2024 Nov 26.\|Int J Med Microbiol. 2020 Jul;69(7):928-931.\|J Antimicrob Chemother. 2017 Jul 1;72(7):1930-1936.\|J Antimicrob Chemother. 2017 Sep 1;72(9):2483-2488.\|J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615.\|J Antimicrob Chemother. 2024 Apr 2:dkae097.\|J Clin Microbiol. 2023 Apr 18;e0164722.\|Microb Drug Resist. 2020 Apr;26(4):334-340.\|Microbiol Spectr. 2023 Apr 24;e0069223.\|Preprints. 2023 Jun 21.\|ACS Infect Dis. 2021 Jun 30.\|Acta Microbiol Immunol Hung. 2021 Jul 29.\|Adv Ther (Weinh). 2024 Jan 12.\|Antibiotics (Basel). 2021 Sep 14;10(9):1110.\|Antibiotics (Basel). 2021, 10(11), 1341.\|Antibiotics (Basel). 2022, 11(10), 1280.\|Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18. \|Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00433-18.\|Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00282-18. \|Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00873-18.\|Antimicrob Agents Chemother. 2022 Jun 1;e0240221.\|Antimicrob Agents Chemother. 2023 Jan 23;e0145922.\|bioRxiv. 2021 Mar 13.\|bioRxiv. 2024 Sep 25:2024.09.25.615047.\|Biosens Bioelectron. 2021 Jul 21;193:113526.\|Cell Rep. 2024 Nov 9;43(11):114962.\|Infect Drug Resist. 2020 Aug 18;13:2883-2890.\|Infect Drug Resist. 2021 Jun 30;14:2499-2507.\|Int J Antimicrob Agents. 2018 Aug;52(2):269-271.\|Int J Antimicrob Agents. 2024 Jun 24:107256.\|Int J Antimicrob Agents. 2024 May 14:107206.\|Int J Infect Dis. 2020 Apr;93:252-257. \|Int J Med Microbiol. 2021 Oct;70(10).\|Int J Mol Sci. 2021, 22(6), 3051.\|J Antimicrob Chemother. 2021 Feb 11;76(3):653-658.\|J Antimicrob Chemother. 2021 May 6;dkab141.\|J Antimicrob Chemother. 2022 Jul 15;dkac232.\|J Antimicrob Chemother. 2023 Feb 13;dkad032.\|J Infect Dev Ctries. 2021 Mar 31;15(3):404-414.\|J Infect Dis. 2019 Jul 2;220(3):484-493. \|Microbiol Spectr. 2022 Aug 16;e0139022.\|Microbiol Spectr. 2022 Aug 24;e0203522.\|Microbiol Spectr. 2022 Dec 8;e0303822.\|Microbiol Spectr. 2023 Nov 20:e0304723.\|Microbiol Spectr. 2024 Sep 3.\|Molecules. 2025 Mar 9;30(6):1224.\|Nature. 2024 Aug;632(8026):893-902.\|Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611.\|PLoS Pathog. 2024 Dec 31;20(12):e1012783.\|RSC Adv. 2023 Nov 30;13(49):34884-34890.\|Sci Rep. 2022 Oct 7;12(1):16814.\|Int J Infect Dis. 2021 Apr 14;S1201-9712(21)00346-5.\|J Clin Microbiol. 2020 Aug 24;58(9):e00932-20.
Smiles	O=S(ON1[C@]2([H])CC[C@@H](C(N)=O)[N@@](C2)C1=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NXL-104 (free acid)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Antibiotic; Bacterial; Beta-lactamase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	265.24
Product Description	Avibactam (NXL-104) free acid is a covalent and reversible non-β-lactam β-lactamase inhibitor which inhibits β-lactamase TEM-1 and CTX-M-15 with IC50s of 8 nM and 5 nM, respectively[1].
Manufacturer - Research Area	Infection
Solubility	DMSO: 125 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14879-10mM-safety-datasheet.pdf